Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Arthritis & Rheumatology (Hoboken, N.J.)|July 28, 2019
Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic SclerosisAlina Soare, Hermina A Györfi, Alexandru E Matei, et al.
Annals of the Rheumatic Diseases|April 27, 2016
Composition of TWIST1 dimers regulates fibroblast activation and tissue fibrosisKatrin Palumbo-Zerr, Alina Soare, Pawel Zerr, et al.
RMD Open|February 28, 2025
Validation of a semi-quantitative method to assess interstitial lung disease severity and progression in systemic sclerosis by standard and low-dose HRCT scansLucas Tschalèr, Suzana Jordan, Trond Mogens Aaløkken, et al.
Rheumatology (Oxford, England)|January 23, 2016
Content validity of global measures for at-work productivity in patients with rheumatic diseases: an international qualitative studySarah Leggett, Antje van der Zee-Neuen, Annelies Boonen, et al.
Annals of the Rheumatic Diseases|February 18, 2015
Digital ulcers predict a worse disease course in patients with systemic sclerosisCarina Mihai, Robert Landewé, Désirée van der Heijde, et al.
Annals of the Rheumatic Diseases|October 25, 2017
Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohortCarina Mihai, Milos Antic, Rucsandra Dobrota, et al.
The Journal of Rheumatology|December 3, 2015
Test-retest Reliability and Correlations of 5 Global Measures Addressing At-work Productivity Loss in Patients with Rheumatic DiseasesSarah Leggett, Antje van der Zee-Neuen, Annelies Boonen, et al.
RMD Open|November 28, 2024
Performance of the EULAR Systemic sclerosis Impact of Disease (ScleroID) questionnaire as a patient-reported outcome measure for patients with diffuse systemic sclerosisRucsandra Dobrota, Alexandru Garaiman, Kim Fligelstone, et al.
Rheumatology (Oxford, England)|July 29, 2022
Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC modelAlexandru Garaiman, Klaus Steigmiller, Catherine Gebhard, et al.
Annals of the Rheumatic Diseases|August 19, 2019
Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrualSerena Fasano, Antonella Riccardi, Valentina Messiniti, et al.
Pageof 7